Table: Selected TLR Ligands in Clinical Trials
Product | Target | Manufacturer | Condition | Phase | Intervention | Status |
| CPG7909 | TLR9 | Coley Pharmaceutical Group | Lymphoma | I/II | CpG injections and radiotherapy http://www.clinicaltrials.gov/ct/show/NCT00185965 | Ongoing |
| Coley/Pfizer | Metastatic breast cancer, renal cell cancer, T-cell lymphoma, non-small cell lung cancer, melanoma | I or II | CpG injection with or without chemotherapy http://www.clinicaltrials.gov/ct/show/NCT00043407 http://www.clinicaltrials.gov/ct/show/NCT00043420 http://www.clinicaltrials.gov/ct/show/NCT00070629 http://www.clinicaltrials.gov/ct/show/NCT00070642 | Ongoing and completed | ||
| Malaria | I | Malaria vaccine with and without CpG 7909 http://www.clinicaltrials.gov/ct/show/NCT00320658 | Recruiting | |||
| CPG10101 | TLR9 | Coley Pharmaceutical Group | Hepatitis C | II | Pegylated interferon plus ribavirin with or without CPG 10101 in hepatitis C patients http://www.clinicaltrials.gov/ct/show/NCT00277238 | Recruiting |
| 1018 ISS | TLR9 | Dynavax | Allergy | II | ISS conjugated to ragweed allergen given to patients with allergic rhinitis http://www.clinicaltrials.gov/ct/show/NCT00346086 | Completed |
| B-cell follicular lymphoma | II | ISS given in conjunction with Rituxan http://www.clinicaltrials.gov/ct/show/NCT00251394 | Recruiting | |||
| Metastatic colorectal cancer | I | ISS in combination with irinotecan and cetuximab http://www.clinicaltrials.gov/ct/show/NCT00403052 | Recruiting | |||
| Hepatitis B | II | ISS with hepatitis B surface antigen compared with commercial hepatitis vaccine (completed in 2004; phase III trial underway in Asia) | Completed | |||
